Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $48
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $44
Promising Potential of Bicara Therapeutics' Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
Wells Fargo Maintains Bicara Therapeutics(BCAX.US) With Sell Rating, Maintains Target Price $8
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Analysts' Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), AstraZeneca (AZN)
Wells Fargo Initiates Bicara Therapeutics(BCAX.US) With Sell Rating, Announces Target Price $8
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $44
Bicara Therapeutics Analyst Ratings
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $48
Bicara Therapeutics Analyst Ratings
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $47
Bicara Therapeutics Initiated at Outperform by Wedbush
Bicara Therapeutics Price Target Announced at $31.00/Share by Wedbush